[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609040":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":20,"collaborators":24,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":11,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":11,"enrollmentInfo":36,"targetDuration":11,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":55,"locationsCount":11},{"fullName":5,"class":6},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"transarterial chemoembolization with FOLFOX plus\u002Fminus intravenous cetuximab\u002Fbevacizumab","EXPERIMENTAL",null,[13],"Procedure: Transarterial chemoembolization",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","Transarterial chemoembolization","Transarterial chemoembolization with FOLFOX plus\u002Fminus intravenous cetuximab\u002Fbevacizumab",[9],{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Junpeng Wang","Chief physician",[25],{"name":26,"class":6},"Peking Union Medical College Hospital","100609040","phase-2-clinical-efficacy-of-transarterial-chemoembolization-in-elderly-patients-with-advanced-unresectable-colorectal-cancer-100609040",false,"NCT07209384","Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer","CLINICAL EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION IN ELDERLY PATIENTS WITH ADVANCED UNRESECTABLE COLORECTAL CANCER","Inclusion Criteria:\n\n* Age ≥ 65 years, gender not restricted Pathologically confirmed advanced colorectal cancer without the opportunity for curative surgery Karnofsky Performance Status (KPS) score ≥ 60, with an estimated survival time ≥ 3 months At least 1 measurable colorectal lesion No prior systemic chemotherapy, or a minimum interval of 6 months between the last chemotherapy and study enrollment Voluntary signing of the informed consent form\n\nExclusion Criteria:\n\n* Concomitant other malignant tumors Presence of gastrointestinal perforation Severe cardiovascular and cerebrovascular diseases Patients with hypersensitivity to study drugs or psychiatric disorders","ALL","65 Years",{"count":37,"type":38},50,"ESTIMATED","INTERVENTIONAL",[41],"PHASE2","We plan to conduct a prospective, two-arm, open-label phase Ⅱ study to evaluate whether transarterial chemoembolization with FOLFOX plus\u002Fminus intravenous cetuximab\u002Fbevacizumab significantly improves the efficacy and safety compared with systemic FOLFOX therapy plus\u002Fminus cetuximab\u002Fbevacizumab in elderly patients with advanced unresectable colorectal cancer.",[44,45,46],"Unresectable Colorectal Cancer","Advanced Malignancy","Elderly (People Aged 65 or More)","NOT_YET_RECRUITING","2025-10-01",{"date":50,"type":51},"2025-10-07","ACTUAL",{"date":48,"type":38},{"date":54,"type":38},"2026-10-01",{"name":22,"class":6}]